Prescribing information

 

   

JAKAVI has a well-characterised safety and dosing profile, with manageable AEs1

The safety profile of JAKAVI® has been consistently demonstrated across 5-year follow-up to the COMFORT-I and COMFORT-II trials, and in real-world studies – with no newly observed patterns of AEs.1–5

Frequency category of adverse drug reactions reported in COMFORT-I and COMFORT-II1

Diagram showing the most commonly reported haematological and non-haematological AEs among patients who received JAKAVI in the COMFORT-I and COMFORT-II trials

COMFORT-I (double blind) and COMFORT-II (open label) were randomised, Phase 3 studies of JAKAVI vs placebo and BAT, respectively (COMFORT-I, n=155 and n=154 for JAKAVI and placebo, respectively; COMFORT-II, n=146 and n=73 for JAKAVI and BAT, respectively). Primary endpoint: proportion of patients achieving a ≥35% reduction in spleen volume from baseline at Week 24 and Week 48, respectively.2,6

Special warnings and precautions include myelosuppression, infections, progressive multifocal leukoencephalopathy and possible withdrawal effects. Please see the Summary of Product Characteristics for more details including possible drug interactions.

 

* Frequency is based on adverse event data. A subject with multiple occurrence of an adverse drug reaction is counted only once in that ADR category. ADRs reported are on treatment or up to 28 days post treatment end date.1
† Frequency is based on all patients exposed to JAKAVI in clinical studies (N=4755).1
‡ Frequency is based on laboratory values. A subject with multiple occurrences of an ADR is counted only once in that ADR category. ADRs reported are on treatment or up to 28 days post treatment end date.1
§ CTCAE version 3.0; grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening.1

 

ADR, adverse drug reaction; AE, adverse event; BAT, best available therapy; CTCAE, common terminology criteria for adverse events; MF, myelofibrosis.

References

  1. Novartis Pharmaceuticals UK Ltd. JAKAVI® summary of product characteristics.
  2. Harrison C, et al. N Engl J Med. 2012;366:787–798.
  3. Russell J, et al. Ruxolitinib in myelofibrosis: a multicentre experience from the east of England. EHA 2017, 22–25 June; Madrid, Spain. Abstract PB2057.
  4. Russell J, et al. Ruxolitinib in myelofibrosis: a multicentre experience in England, Northern Ireland and Wales. EHA 2018, 14–17 June; Stockholm, Sweden. Abstract PS1369.
  5. Verstovsek S, et al. J Hematol Oncol. 2017;10:55.
  6. Verstovsek S, et al. N Engl J Med. 2012;366:799–807.
HCP20-C024c(1) August 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]